insulin

Australian scientists have designed a new capsule that could mean diabetics might one day swallow their insulin instead of injecting it. The design also has potential uses for delivering other protein drugs, such as antibiotics and cancer treatments.Type 1 diabetes is an autoimmune disease where the body’s immune system attacks the insulin-producing beta cells of the pancreas, causing little to no insulin to be secreted. Type 1 diabetics – and some type 2 diabetics – therefore have to inject themselves with insulin…

Type 1 diabetics must constantly control their blood glucose with insulin. It’s a Goldilocks-type situation: administer too much insulin, and they risk low blood glucose (hypoglycemia), while too little can lead to high blood glucose (hyperglycemia). Researchers have developed a self-adjusting nanoparticle-based insulin formulation that may go some way towards improving blood glucose control.Type 1 diabetes (T1D) is an autoimmune disease where the body’s immune system attacks the insulin-producing beta cells of the…

Gov. Gavin Newsom announced a new $50-million contract with the nonprofit generic drugmaker Civica to produce insulin under the state’s own label during a news conference Saturday in Downey.Newsom originally declared his intent to produce generic drugs three years ago in an attempt to lower the cost of pharmaceutical products for Californians who struggle to afford often life-saving medication. The deal with Civica would provide the first pharmaceutical product made under the CalRX brand of generic drugs. Under the deal,…

French drugmaker Sanofi SA said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big pharmaceutical companies facing pressure to reduce the cost of diabetes treatments.Sanofi plans to take a 78% list-price reduction on Lantus, the company’s most widely used insulin in the U.S., and a 70% cut on its Apidra product starting in January 2024, the company said Thursday.  Sanofi also said it would cap a Lantus patient’s monthly out-of-pocket cost…

Novo, one of the biggest sellers of insulin in the U.S. and around the world, said Tuesday it would cut the list price of its NovoLog insulin by 75% and the prices for Novolin and Levemir by 65% starting in January 2024.  In addition, Novo plans to cut prices for its unbranded insulin products to match the reduced price of Novo’s corresponding brands. “We have been working to develop a sustainable path forward that balances patient affordability, market dynamics and evolving policy changes,” said Steve Albers,…

Sen. Bernie Sander’s new bill will cap drug prices to what Eli Lilly’s Humalog cost when it was first released in 1996.Photo: Spencer Platt (Getty Images)On Thursday, Vermont Sen. Bernie Sanders and a gaggle of Democrats introduced a new bill that would cap insulin drug prices to just $20 per vial no matter which company is making it.The bill, called the Insulin for All Act of 2023, caps the price at what the major pharmaceutical company Eli Lilly originally setfor a month’s supply of its insulin treatment Humalog back…

US pharmaceutical giant Eli Lilly announced Wednesday it would cut the cost of its insulin by 70 percent, with President Joe Biden calling on others to follow suit to tackle soaring drug prices.​Manufacturers have ratcheted up insulin prices in recent years, hitting millions of Americans living with diabetes – and drawing sharp political criticism.​"Insulin costs less than $10 to make, but Americans are sometimes forced to pay over $300 for it. It's flat wrong," said Biden in a statement. He hailed Eli Lilly's price cut…

Image: Daniel Beckemeier (Shutterstock)An Insulin drugmaker announced it is making its drug more affordable for some diabetics and is capping the out-of-pocket cost at $35 per month. Eli Lilly is making Insulin immediately available to seniors on Medicare. It’s welcome news to the many Americans who rely on insulin, as the cost of care has soared in recent years.The company is automatically applying the price cap for Insulin to seniors who have private insurance and those without can sign up for Eli Lilly’s copay…

Eli Lilly & Co., facing pressure to curb diabetes-treatment costs, will cut the list prices for its most commonly prescribed insulin products by 70% and take other steps to make it easier for patients to afford the drugs.  The Indianapolis-based company said Wednesday the 70% price cuts will take effect in the fourth quarter for Humalog and Humulin, its two biggest-selling insulin products.  The company also said that on May 1 it would…

With the incidence of type 2 diabetes increasing alarmingly, science is looking to genetics to better understand the processes underlying this chronic illness. A new study has isolated a gene not previously associated with diabetes that seems to lead to the pancreatic dysfunction that causes the disease.The International Diabetes Federation (IDF) predicts that, by 2045, 12.2% of the world’s population will be living with diabetes. Type 2 diabetes (T2D) is the more prevalent form of the disease, accounting for around 90%…